LMAT as reported
LeMaitre Vascular, Inc. reported $241M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed.
$241M
Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied
- Net Income
- $62M
Net Income · +38% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $79M
Free Cash Flow · +92% year on year · trailing twelve months to Q1 2026
- Op Margin
- 26%
Op Margin · trailing twelve months to Q3 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $241M | n/a | Q3 2025 |
| Net Income | $62M | +38% | Q1 2026 |
| EPS | $2.71 | +38% | Q1 2026 |
| Gross Margin | 71% | n/a | Q3 2025 |
| Op Margin | 26% | n/a | Q3 2025 |
| Net Margin | 22% | n/a | Q3 2025 |
| ROE | 14% | n/a | Q1 2026 |
| ROA | 9.1% | n/a | Q1 2026 |
| ROIC | 16% | n/a | Q4 2021 · 17 quarters behind |
| Free Cash Flow | $79M | +92% | Q1 2026 |
| P/E | 29.4 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
LeMaitre Vascular, Inc. (LMAT) - Revenue & ProfitRevenue & ProfitLeMaitre Vascular, Inc. (LMAT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #9 of 27 by Smart Score